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A central challenge in the fight against tuberculosis (TB) is overcoming the barriers 
presented by TB therapy, itself.  Side-effects are common and treatment courses are 
long, extending well beyond a year in some cases of drug-resistant disease.1,2 Poor 
treatment adherence has been linked to microbiologic failure, disease relapse and the 
emergence of drug resistance.3,4 
 
In response, and in an effort to promote treatment completion, the Centers for Disease 
Control (CDC) and the World Health Organization (WHO) have advocated for directly 
observed therapy (DOT), wherein the ingestion of each dose is directly monitored.1,5,6 In 
many areas, DOT is the current standard of care, though employing DOT in a patient-
centered and efficient fashion can be challenging. Scheduling in-person DOT visits is 
logistically complicated, resource intensive (for patients and TB programs), and can 
increase both patient and program-level costs. In some individuals, logistical barriers 
and perceived stigma related to DOT have led to feelings of humiliation, loss of control 
and stress.7,8 
 
To overcome these barriers, video-based DOT (vDOT) has been proposed as an 
alternative to in-person observation.1,9,10 Herein, pill ingestion is monitored remotely via 
digital video capture. vDOT has been implemented using synchronous technologies, 
such as Skype and FaceTime,11-14 as well as asynchronous ones, wherein recorded 
videos are uploaded and digitally stored for future review.15 While both the CDC and 
WHO support the use of vDOT, data on the real-world implementation of vDOT remains 
 iii 
limited. To this end, we present two studies which broaden our understanding of vDOT 
by exploring its potential role in two distinct clinical settings, among two very different 
patient populations. 
 
In Chapter 1, we present the results of a pragmatic, prospective, pilot implementation of 
vDOT at three TB clinics in Maryland, US. A mixed-methods approach is employed to 
assess (1) effectiveness, (2) acceptability and (3) cost.  In Chapter 2, we extend the use 
of vDOT into a high TB burden, low resource setting, though a prospective, pilot 
implementation of vDOT in Pune, India. 
 
Our work shows that vDOT may be a feasible and acceptable approach to TB treatment 
monitoring, both within the US and India. Further, vDOT may be associated with cost-
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Video directly observed therapy (vDOT) is effective in diverse patient populations and 
represents an important tool in patient-centered tuberculosis (TB) care.  Further, the 























Directly observed therapy (DOT) remains an integral component of treatment support 
and adherence monitoring in tuberculosis care.  In-person DOT is resource intensive 
and often burdensome for patients.  Video DOT (vDOT) has been proposed as an 
alternative to increase treatment flexibility and better meet patient-specific needs.    
 
Methods.  
We conducted a pragmatic, prospective, pilot implementation of vDOT at three TB 
clinics in Maryland, USA.  A mixed-methods approach was implemented to assess (1) 
effectiveness, (2) acceptability and (3) cost.  Medication adherence on vDOT was 
compared to that under in-person DOT.  Interviews and surveys were conducted with 
patients and providers before and after implementation, with framework analysis utilized 
to extract salient themes.  Lastly, a cost analysis assessed the economic impacts of 
vDOT implementation across heterogeneous clinic structures.    
 
Results. 
Medication adherence on vDOT was comparable to that under in-person DOT  (94% vs 
98%, p=0.17), with a higher percentage of total treatment doses (inclusive of 
weekends/holidays self-administration) ultimately observed during the vDOT period 
(72% vs 66%, p=0.03).  Video DOT was well received by staff and patients alike, who 
cited increased treatment flexibility, convenience and patient privacy.  Our cost analysis 
 4 
estimated a savings with vDOT of $1,391 per patient, for a standard six month 
treatment course.   
 
Conclusions. 
Video DOT is an acceptable and important option for measurement of TB treatment 
adherence, and may allow a higher proportion of prescribed treatment doses to be 
observed, compared to in-person DOT.  Video DOT may be cost-saving and should be 


















Tuberculosis (TB) remains a global pandemic responsible for nearly two million deaths 
annually.1  In the United States (US), previously reported declines in incident disease 
have stagnated in recent years.2,3  
 
A central challenge in the fight against TB is overcoming the barriers presented by TB 
therapy, itself.  Side-effects are common and treatment courses are long, extending well 
beyond a year in some cases of drug-resistant disease.4,5  Poor treatment adherence 
has been linked to microbiologic failure, disease relapse and the emergence of drug 
resistance.6,7  
 
In response, and in an effort to promote treatment completion, the Centers for Disease 
Control (CDC) and the World Health Organization (WHO) have advocated for directly 
observed therapy (DOT), wherein the ingestion of each dose is directly monitored.4,8,9 
Programmatic uptake of DOT has been widespread.  Within the US, DOT is now the 
standard of care, and even codified into law in many states.10    
 
Despite broad policy support, more recent studies looking at the effectiveness of DOT 
on treatment outcomes have been mixed, likely owing to heterogeneous approaches to 
implementation.11-13  Nonetheless, current treatment guidelines, including that from the 
CDC, continue to underscore the importance of DOT, but now emphasize its role as just 
one component of a multifaceted approach to case management and treatment 
support.4,14  Further, “To be consistent with the principles of patient-centered care, 
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decisions regarding the use of DOT must be made in concert with the patient.”4  As 
such, DOT implementation must account for patient-specific needs, and should ideally 
couple observation of pill ingestion with strategies for adherence support.  
 
Employing DOT in a patient-centered fashion can be challenging.  Scheduling in-person 
DOT visits is logistically complicated, resource intensive (for patients and TB programs), 
and can increase both patient and program-level costs. In some individuals, logistical 
barriers and perceived stigma related to DOT have led to feelings of humiliation, loss of 
control and stress.15,16  In some situations, DOT requirements may therefore represent 
a barrier to adherence. What’s more, provisions for DOT may impact provider 
prescribing practices. While updated TB guidelines advocate daily therapy (i.e. 7 
days/week), our experiences suggest health departments commonly dose TB 
medications Monday to Friday (M-F, i.e. business days) only, or intermittently (i.e. 3 
days/week), in an effort to facilitate in-person DOT.  
 
To overcome these barriers, video-based DOT (vDOT) has been proposed as an 
alternative to in-person observation.4,14,17  Early in 2017, the CDC released at toolkit for 
the implementation of vDOT within TB programs.18  However, given the limited 
experience with vDOT, the guideline cautions against its use in complex patients, 
including those with “adherence issues,” “language barriers” and “multi-drug resistance” 
and acknowledges the need for operational research.  This approach, however, may 
restrict usage in those with complex treatment factors that could potentially benefit most 
from the added flexibility provided by vDOT.   
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As such, we designed a pilot implementation study to address several gaps in our 
current understanding of vDOT implementation.19-27  We utilize a mixed methods 
approach to evaluate (1) feasibility, (2) accessibility and (3) costs when implemented 
under real world conditions. Firstly, we sought to understand feasibility and acceptability 
in broad patient populations, including those with previously poor adherence and drug-
resistant disease. Secondly, we sought to assess effectiveness for observation of 
therapy, as well as costs. Finally, we sought to describe implementation challenges and 




We conducted a pragmatic, prospective, pilot implementation study.  Our objective was 
to assess the feasibility, acceptability, and cost of vDOT utilizing a HIPAA-compliant 
mobile app, miDOT (emocha Mobile Health Inc.), for TB treatment monitoring, 
adherence support and case-management (see Supplement Figure 1).  The study was 
carried out within three public health TB clinics in Maryland, USA, which service a mixed 
urban/suburban population.  Protocols were approved by the ethics committees at 
Johns Hopkins University, the Baltimore City Health Department and the Maryland 






All adult patients receiving active TB treatment or short course isoniazid/rifapentine-
based latent TB therapy were eligible for participation.  Inclusion required patients be 
³18 year of age and to have  ³2 months of therapy remaining.  All patients initiated TB 
therapy with in-person DOT, though could transition to vDOT at any point during their 
treatment course.  The decisions to offer vDOT were made by non-conflicted health 
department clinicians, without explicit exclusion of non-English speakers, or those with 
multi-drug resistant disease or poor prior adherence. Patients interested in utilizing 
vDOT provided written informed consent, and those without access to a smartphone 
were provided one by the study.   
 
TB treatment 
Treatment decisions were clinic-directed according to Maryland State and CDC 
guidelines, regardless of DOT modality.4,28 Under these guidelines drug regimens 
generally rely on either daily or intermittent (3 day/week) dosing.   While studies have 
not compared the efficacy of 5 vs 7 doses per week, under DOT, both regimens were 
referred to as “daily.”4  Each clinic defined treatment completion and success based on 
ingesting a set number of target doses.  Any missed doses were added to the end of 
therapy, extending treatment duration.  At baseline, for daily dosing, TB clinics 
combined in-person DOT 5 day/week (M-F), with weekend (and holiday) self-
administration, the latter not contributing to the overall dose target.  While on vDOT, 
dosing frequency (i.e. 5 days/week versus 7 days/week) and whether to observe and 
count weekend doses towards an overall dose target was left to clinic discretion.  
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Patients were sent twice daily SMS reminders in the absence of submitted videos and 
were prompted to document side-effect prior to each submission (see Supplement for 
more on miDOT specifics).  All patient data, servers, and transmissions were encrypted 
to protect patient privacy, and the app automatically deleted videos from the 
smartphone upon transmission (Figure 1).    
 
Feasibility and effectiveness 
We assessed two primary outcomes, acknowledging a lack of consensus definition on 
measurement of adherence and differences in programmatic practices related to 
‘expected’ doses.  The first was treatment adherence, or the proportion of ‘expected’ 
DOT (in-person or video) that was successfully completed, in which ‘expected’ dose 
was defined by the TB clinic (usually omitting weekend and holiday self-administered 
doses) (see Supplement Figure 2). Given the goal of DOT is to observe all prescribed 
doses, as a second measure, we calculated the observable fraction, or the proportion of 
total doses (inclusive of weekends, holiday or other ‘self-administered’ doses) 
completed under observation (either in-person or by video).  All patients received case-
management per routine at each TB clinic site irrespective of DOT modality; this 
generally included case-management phone calls or visits following missed doses or 
reported side-effects. 
 
Differences pre/post vDOT implementation were evaluated using paired t-tests, though 
our study was not powered, nor specifically intended, to detect between-group 
differences.  All analysis was conducted in STATA 14.  
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Acceptability 
Qualitative research methodology was employed to explore participant and staff 
perceptions of in-person and vDOT.  All clinic staff (DOT workers, case-managers, 
clinicians) and enrolled patients were approached to complete surveys and in-depth 
interviews pre/post vDOT implementation; a separate informed consent was used and 
patients could enroll in the study without participation in the qualitative component.  All 
interviews were digitally recorded and transcribed verbatim.  Each transcription was 
reviewed by two study members and an iterative, open-coding strategy with framework 
analysis was employed to identify salient themes.29 
 
Cost 
A cost analysis was conducted using time motion studies and an ingredients-based 
approach in which unit-costs for labor, equipment and consumables were multiplied by 
quantities required for in-person DOT and vDOT (see Supplement Table 5).  To allow 
equal comparisons, final calculations were standardized to a six-month treatment 
course (daily therapy) for drug-sensitive TB; based on clinic practices, primary analysis 
was standardized to a M-F dosing strategy, with a secondary analysis comparing 7 
day/week therapy.  
 
In base-case analysis, we incorporated costs for a licensed practical nurse (LPN) 
utilizing a department of health (DOH)-owned vehicle for community-based, in-person 
DOT.  For vDOT, the base-case scenario incorporated costs of a program-provided 
 11 
smartphone (and associated data costs), and an estimated commercial software costs 
of $50 per patient, per month (personal communication with emocha).  
 
Sensitivity analysis was conducted to evaluate variations in consumable, labor, and 
equipment costs with consideration of programmatic heterogeneity in the 
implementation of in-person DOT (e.g., type of staff conducting DOT, vehicle used and 
travel distance) and vDOT (e.g., range of software-associated costs from a high of $100 




A total of 28 patients were enrolled and treated between March 2016 and August 2017.  
Of these, 25 received active TB therapy and three received weekly rifapentine/INH for 
LTBI (Table 1).  Ninety-three percent of patients were foreign born.  Only three patients 
(11%) required use of a study phone for vDOT.  Thirty-nine percent had extrapulmonary 
disease, consistent with regional and national epidemiology.30,31 
 
Among active TB patients prescribed ‘daily’ therapy (at any point during their treatment), 
a dosing strategy of DOT 5 times/week (M-F) with weekend self-administration was the 
most common observation strategy regardless of DOT modality, though was more 
frequent during the in-person period (100% vs. 76%, p=0.01).  Overall, intermittent 
thrice weekly therapy was utilized less commonly on vDOT than during in-person (24% 
vs 16%, p=0.32).  No patients received seven days of in-person DOT, though two were 
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transitioned to this schedule while on vDOT.  Mean time on therapy for in-person DOT 
and vDOT was 12.2 and 19.2 weeks, respectively (p=.01).   
 
Feasibility/effectiveness: 
Measured Adherence was high irrespective of DOT strategy: median 98%(IQR 90-100) 
during in-person DOT and 94% (IQR 88-98) while on vDOT (p=0.17, Table 2).  The 
median observable fraction (i.e. proportion of all prescribed doses observed) was 
statistically lower during the in-person DOT period (In-person=66% [62-72] vs 
vDOT=72% [67-92], p=0.03).  Overall, only 15% of patients had more than 80% of total 
prescribed doses verified through observation during in-person DOT, compared to 36% 
during vDOT (p=0.01), a consequence of self-administered weekend and holiday doses. 
 
Fifty-seven percent of patients had at least one rejected video (mean 1.8, range 0-11), 
representing 2.1% of all submitted videos (2,350).  The two most commonly cited 
reasons for rejection were “Medication dose not visible” and “Poor video quality.”  
 
A total of four patients traveled internationally while on miDOT, though continued to 
successfully submit videos.  Two patients were transferred from health department care 
after permanently leaving the US prior to treatment completion (one to Liberia and one 
to Ivory Coast); both had been on vDOT for >16 weeks with an adherence of 72% and 
87%, respectively, at the time of study exit.  A single patient had vDOT discontinued 
prematurely after five weeks due to an adherence of 63% (on 7 days/week of DOT); the 
patient had been on in-person DOT for 17 weeks prior to vDOT, expressed an interest 
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to return to her prior routine of in-person DOT and successfully completed therapy with 
an adherence of 100%. 
 
Acceptability: 
All staff and patients were approached to explore attitudes towards in-person DOT and 
vDOT. Twenty staff participated before vDOT implementation, and 16 post-
implementation; Twenty-five patients were included before vDOT, with 10 providing 
post-treatment feedback. vDOT adherence did not differ between patients completing 
and those not completing post-intervention qualitative assessment (adherence 89% vs 
90%, p=0.92). 
 
At baseline, nearly all staff felt in-person DOT provided beneficial social support (95%), 
and only a few (10%) considered self-administered therapy to be sufficient alone (see 
Supplement Tables 1 and 2 ).  Both staff (95%) and patients (92%) were comfortable 
using smartphones from the outset.  Following the intervention, all surveyed patients felt 
the miDOT platform was “easy to use” and  preferred over in-person DOT.   
 
Themes related to this preference for vDOT were common during interviews and 
focused on convenience and increased flexibility (Table 3 and Supplement Tables 3 and 
4).  Both patients and staff commented on the limitations of in-person DOT when 
managing complex schedules.  Speaking to the impact of foreign travel, one staff 
member noted, “We try to arrange jurisdictional coverage during [travel] times, but if it's 
outside the country, you really can't.”  
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Another prominent theme was the impression that in-person DOT threatened patient 
privacy.   This concern appeared to be driven by the public optics of daily visits (at 
home/work) from DOH staff.  In speaking to this concern one patient stated, 
“Sometimes they meet me…at work…I’m afraid I’ll be seen.”  The added flexibility 
provided by vDOT seemed to allay these fears.  As one nurse commented, “You can do 
[vDOT] in your car on the way to work. You can sit out in your driveway and do it … it’s 
more private than having a nurse come to the house.”  Notably, no patients or staff 
raised concerns regarding data security with the use mobile phones to share private 
health information.  
 
While an uncommon theme, one nurse manager discussed a fear of displacement 
among staff, stating “some DOT workers worry video DOT will take their jobs.” At the 
same time, she went on to highlight the ability of vDOT to maximize clinic resources 
noting “[vDOT] actually helps because a lot time we're short [staffed and] when you 
have this … you don't want your workers running around the streets all day.”  Further, it 
was noted that DOT workers could take on larger patient panels and spend more 
individual time face-to-face with those remaining on in-person DOT. Additional 







In our primary analysis (observation 5 days/week for a 6 month course), we projected 
that vDOT implementation would lead to an incremental cost savings of $1,391, per 
person compared to using in-person DOT (Table 3).   
 
Cost for in-person DOT was driven largely by labor.  In our primary analysis, labor costs 
totaled $1,838, amounting to >90% of the overall DOT expenditure for a standard TB 
treatment course.  Labor costs varied markedly in sensitivity analysis based on health 
care worker type (e.g., community health worker [CHW] versus registered nurse [RN]); 
overall we estimated total in-person DOT costs at $866 to $5,857.  
 
For miDOT, we found costs were driven by consumables, namely estimated software 
($0-$100 per month) and data costs.  In our base-case consumable costs totaled $495 
($0 to $900), comprising two-thirds of net treatment costs. Labor costs were low, 
totaling only $131 ($62-$413) and accounting for <20% of overall costs ($674). At the 
highest estimates of consumable costs ($900), driven by a monthly charge of $50 for 
data and $100 for software, vDOT was still associated with a cost savings of roughly 
$1,000 per treatment course, compared to in-person DOT.   
 
DISCUSSION 
In our pragmatic mixed-methods implementation of treatment monitoring strategies at 
three separate public health TB clinics in Maryland, we found broad patient and staff 
acceptability of vDOT, with similar adherence and an increased proportion of prescribed 
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doses confirmed through observation.  Our economic evaluation suggests potential 
cost-savings with vDOT, when compared to exclusive usage of in-person DOT.  Our 
study is unique compared to prior evaluations of vDOT in its broad patient inclusion 
criteria, allowing for a real-world assessment and insights related to vDOT 
implementation.  In-depth interviews with patients and staff revealed that TB programs 
considered vDOT a preferred option for patients in whom in-person DOT was logistically 
infeasible (e.g., complex schedules or travel where the alternative was self-
administration) or represented a barrier to care (e.g., stigma).  Program managers 
reported that associated time- and cost-savings allowed task-shifting with redistribution 
of limited clinic resources.  Overall, our results suggest that vDOT is able to more 
effectively measure TB treatment adherence (including weekends and holidays) 
compared to in-person DOT, and can be successfully integrated into patient-centered, 
individualized case-management plans that result in high rates of adherence and 
treatment success.   
 
Our study had several important limitations.  Given current TB case rates, our sample 
size was modest and we were not powered to identify small changes in adherence.  
Nonetheless, we found improvements in the ‘observable fraction’ of prescribed doses 
with vDOT, and our study is strengthened by in-depth qualitative and cost analyses that 
will help guide future larger scale public health implementations.  We did not assess for 
clinical end-points, such as sputum conversion or disease relapse. Our study design did 
allow for within patient comparisons, but must be interpreted cautiously due to potential 
for time-varying confounders during, such as medication adherence, which is known to 
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decline as patients feel better and undergo treatment fatigue.32  These factors could 
have reduced the observed vDOT adherence compared to in-person DOT, given vDOT 
initiation later in the treatment course.  Lastly, our study sample was based on clinic 
(and patient) discretion and not randomized; as such, our conclusions may not apply to 
all patients indiscriminately.  Nonetheless we included a range of TB patients, from the 
latently infected or to those with extrapulmonary disease, and did not exclude patients 
based on prior adherence.  Furthermore, it is important for TB programs to consider that 
while observation of pill ingestion may facilitate measurement of adherence, it is not the 
sole determinant of one’s adherence; reported adherence and treatment outcomes may 
therefore differ according to how DOT services are integrated into broader case-
management strategies.  At our study sites, all patients continued to receive dedicated 
case-management and other adherence support interventions per routine, irrespective 
of DOT modality (particularly after missed doses or reported side-effects).  As such, our 
quantitative and qualitative results provide support for the promotion of individualized 
case-management plans, and argue against a ‘one size fits all’ strategy for providing 
treatment support and treatment monitoring.  
 
Overall, our study provides needed insights on key aspects of vDOT usage related to 
patient selection, implementation, effectiveness and costs.  We found that many 
patients were ultimately enrolled because of social factors thought to preclude, or at 
least impact, the ability to conduct in-person DOT.  For example, several patients were 
able to have treatment observation and adherence measurements using vDOT while 
traveling outside of the US. Such examples have practical implications. In most public 
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health TB programs, prior to vDOT implementation, such doses (taken under self-
administration) would not have ‘counted’ towards treatment progress (i.e. would need to 
be made up), ultimately prolonging treatment.  
  
Beyond facilitating early recognition of poor adherence or side effects, DOT also has 
other critical roles in promoting successful TB control.  In the absence of a biological 
marker for disease cure, TB programs base treatment completion on a pre-specified 
number of treatment doses.4  When applied consistently DOT therefore serves as a key 
method to measure adherence, and represents a mechanism to track treatment 
progress.  In this regard, our study highlights an important consideration in adherence 
measurement and dosing frequencies. Current treatment guidelines have placed 
increasing emphasis on daily (7 days/week) therapy, though still accept a 5 day/week 
alternative “daily” schedule (for drug sensitive disease) acknowledging “there are no 
studies that compare 5 to 7 daily doses.”4  Given logistical constraints, many TB 
programs in the US utilize a hybrid treatment schedule, wherein 5 days of DOT (M-F) is 
coupled with self-administered weekend doses; some programs omit weekend doses 
altogether.  Self-administered weekend (or holiday) doses are generally not applied to 
the overall treatment dose count or adherence calculations (i.e. they are not ‘expected’, 
and are not ‘made up’ if missed). In effect, with current practices, ‘in-person DOT’ is 
only able to measure 5 of 7 (71%) prescribed weekly doses. 
 
We therefore a priori chose to report a related metric, the observable fraction, to 
quantify the true percent of prescribed doses, inclusive of weekend self-administration, 
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that could be measured through observation (in-person or video). Prior to the study, we 
assumed that clinics would move away from intermittent dosing regimens, in favor of 7 
days/week therapy upon transition to vDOT.  Ultimately we did see a significant 8% 
increase in the observable fraction upon transition to vDOT, however the absolute 
fraction was only 76% (vs 68% with in-person DOT).  This result stemmed from the fact 
that only two participants had their ‘monitoring frequencies’ increased to 7 days/week on 
vDOT, likely a result of entrenched provider practices. For example, some clinics 
explicitly instructed patients not to submit weekend videos, while others actively 
‘rejected’ any such submissions. Our study demonstrates the need to adapt clinic 
workflows to this new monitoring approach, as vDOT ultimately enables the expansion 
of treatment monitoring to 7 days/week and eliminates the need for self-administered 
doses.  This increase in the number of observable doses is likely to reduce overall 
treatment duration by eliminating the need to make up extra doses related to self-
administered or unobserved doses (under the assumption that programs only count 
observed doses towards treatment progress).  
 
Finally, our study provided the first in-depth cost analysis of asynchronous vDOT.  We 
found marked heterogeneity across health departments, both in terms of staffing and 
the operational implementation of in-person DOT.  Despite this diversity, we estimated 
vDOT to save programs at least $1,000 per patient if implemented for a standard six 
month treatment course (versus 5x per week in-person DOT).  When considering TB 
clinic costs and staffing overall, it is important to acknowledge that DOT represents one 
of several TB treatment and case-management related activities. During our in-depth 
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interviews, a single CHW expressed concerns about being displaced by this new 
technology; such considerations need acknowledgment during implementation.  
However, several staff also presented alternative perspectives noting vDOT allowed for 
increased time and attention to be directed toward other required activities (e.g., contact 
investigations, patient counseling and social support). In an era of increasing 
responsibilities and limited funds, maximizing staff potential is often a necessity.  
 
Overall, our study contributes to the growing literature on usage of alternative modalities 
for TB treatment monitoring, and expands on prior efforts by demonstrating feasibility, 
acceptability, and cost-savings in a previously unstudied environment and among a 
broader patient population, compared to prior studies.20-23  By using a rigorous mixed-
methods implementation science approach, our results identified and highlighted 
several important considerations related to patient selection, treatment frequency, and 
measurement of adherence that will guide policy makers and TB programs considering 
vDOT implementation. Importantly, our findings suggest the need for flexible, 
individualized case-management plans that consider patient needs while achieving 







Funding. This work was supported by the Small Business Innovation Research (SBIR) 
program at the National Institutes of Health (NIH) awarded to emocha Mobile Health 
Inc. [grant number R43 MD010521].  Additional National Institutes of Health support 
was provided through a Postdoctoral Training Grant [grant number T32 AI007291-25 to 
S.B.H.). 
 
Potential conflicts of interest.  Dr. Shah is one of the inventors of the miDOT technology. 
Under a license agreement between emocha Mobile Health Inc. and the Johns Hopkins 
University, Dr. Shah and the University are entitled to royalties on technology described 
in this article. This arrangement has been reviewed and approved by the Johns Hopkins 
University in accordance with its conflict of interest policies.  To mitigate any potential 
conflicts of interest all clinical decision making regarding use of miDOT or enrollment in 
the study was made by non-conflicted department of health clinicians and staff; M.S. 
recused himself from all data analysis but assisted with results interpretation.  
 
Acknowledgements. We would like to thank the hard work of those providing clinical 
care each of our three study sites.  We would also like the thank the leadership and 
development team at emocha Mobile Health Inc. including Sebastian Seiguer JD MBA, 
Katrina Rios and Gorkem Sevic MSE.   
 
Author Contributions. Study concept and design: M.S. Acquisition of data: S.B.H. 
Statistical analysis:  S.B.H. Qualitative coding: S.B.H, A.Z. Data interpretation: S.B.H, 
M.S. Drafting of initial manuscript: S.B.H. Clinical revision of manuscript: All authors.  
 22 
SUPPLEMENT 
Description of miDOT platform 
Upon opening the app, patients were automatically navigated through a series of 
windows which screened for side-effects, reviewed treatment regimen, and ultimately a 
video-capture interface where they recorded pill ingestion (Supplementary Fig 1).  Any 
noted side-effects were automatically routed to the miDOT provider portal for follow-up.  
Twice daily text-message reminders were automatically sent in the absence of expected 
submissions by the software. Recorded videos were encrypted and stored within 
internal phone memory only until successful upload, after which they were automatically 
deleted . An encrypted transmission tunnel was used to access patient data from 
provider desktops (Figure 1).  Given the asynchronous nature of miDOT, clinic staff 
were able to review submitted videos at any point following digital capture and 
transmission.   
 
Supplemental Methods 
Outcomes of interest   
We considered two primary outcomes (Supplement Figure 2).  Adherence was 
measured as the proportion of expected DOT ultimately completed, whether verified by 
in-person or video observation.   Observable fraction considered the proportion total 
planned treatment doses (including weekend/holiday self-administered doses) observed 
(in-person or by video). For the latter measurement, ‘observation’ was defined loosely 




For in-person DOT, dose administration was retrospectively abstracted from paper 
charts.  During the miDOT phase, patient dosing was prospectively monitored via the 
miDOT system (provider web interface).  All decisions regarding video classification (i.e. 
reject vs accept), were made by unbiased clinic providers.  While the miDOT platform 
automatically tallies doses and calculates adherence, for accuracy (and as a check on 
the system) all miDOT dosing was abstracted to paper calendars and then tallied by 




One MDR patient was included in our study cohort.  This patient transferred into our 
jurisdiction mid- continuation phase (no injectable) and, given patient-specific needs, 
was started directly on vDOT 7x per week.  She successfully completed therapy after 36 
weeks of vDOT. 
 
Qualitative results 
Surveys and in-depth interviews were conducted with patients and staff, both before 
and after vDOT implementation.  Interviews were transcribed verbatim and an open-
coding strategy was utilized to identify salient themes.  An inclusive list of themes is 
reported below (Supplement Table 3 and Table 4), with a subset, representing the most 




Time motion studies 
DOT workers were found to travel an average of 5.4 miles per day, though differences 
in population density and county size led to marked variability, with sites reporting daily 
travel anywhere between three and thirteen miles.  Time per patient per day (inclusive 
of travel) also varied, ranging from 23 to 89 minutes, with 47 minutes used in our base-
case. 
 
Time spent, per patient, on DOT was much shorter during the miDOT period.  Time 
motion studies showed a range of two to eight minutes per patient, with three minutes 
ultimately used in our base case.  
 
Clinical variability 
Significant heterogeneity was observed in the DOT delivery structure between health 
departments (see Supplement Figure 2).  Each site had a nurse administrator 
overseeing one or more nurse case-managers, though the educational 
training/background of those conducting DOT ranged from that of a CHW, with no 
specific health training, to an LPN to an RN.  CHWs were generally tasked only with 
DOT-related activities, while those with more robust clinical training (ex RNs) often had 
additional clinical roles such as latent tuberculosis (LTBI) screening, phlebotomy and 
vaccine administration (non-TB related).  The average DOT caseload was 15, though 
ranged from as few as 3 to as many as 22.  In terms of transportation, some sites 
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Age, yr (median, IQR) 32 (23-49) 
Female, n (%) 16 (57) 
Foreign born, n (%) 26 (93) 
Origin, n (%) 
     United States 
     Africa 
     Latin America 
     South Asia 
     East Asia 








Time in US, yr (median, IQR)1 5 (3-15) 
Limited or no English2, n (%) 7 (25) 
Travel to TB endemic country within 5 years, n (%) 19 (67) 
Highest level of education reached, n (%)2 
     Grade school 
     High school 
     College 






Employment, n (%) 
     Full-time 
     Part-time 





Annual household income,3 n (%) 
     < $20,000 
     $20,000 - $49,999 
     $50,000 - $100,000 






Substance use, n (%)3,4 
     Tobacco 
     Alcohol 





Comorbidities, n (%) 
     HIV infected 
     Hypertension 
     Diabetes 






Taking daily (non-TB) medications, n (%) 6 (21) 
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Technology, n (%) 
     Regular access to smartphone 




Tuberculosis type, n (%) 
     Pulmonary 
          Smear positive 
          Smear negative 
     Exclusively extrapulmonary 







MDR disease, n (%)6 1 (4) 
 
1 Calculated for foreign-born individuals only, those reporting “less than one year” were 
considered to have been in US for six-months for statistical purposes  
2 Included six Spanish speakers and one Oromo 
3 Excludes those for which data unknown 
4 Represents three separate patients 
5 All three phones were returned at study completion in good working order 

















Table 2 (1.2): Primary outcomes by DOT strategy 
 
+ Only participants treated for active TB included (n=25).  
1 Percent of “expected” DOT doses (in-person or video) completed, excluding self-administered 
doses (i.e. weekends or clinic holidays).  An additional, less stringent analysis was also 
conducted wherein “completed” vDOT was loosely defined to include both verified and 
rejected miDOT videos: in-person 98% (90-100) vs vDOT 96% (89-100), p=0.37.  
2 Percent of total planned doses (inclusive of weekend/holiday self-administered) that were 
observed (in-person or video).  For vDOT, “observation” was loosely defined to include all 
forms of uploaded miDOT videos (verified, rejected, unexpected), though only one video was 
counted for a given dosing day.  An additional, stricter analysis was also conducted wherein, 
for vDOT, “observation” referred only to verified videos: in-person 66% (62-71) vs vDOT  70% 
(63-90), p=0.22.  
3 Total number of regimens exceeds sample size (n=25, active TB only) as some participants 
had more than one dosing frequency during their therapy.  
Variable In-person DOT vDOT P 
Adherence (%)1 
        Median (IQR) 







Observable Fraction (%)2 







Number (%) of patients with observable fraction 
greater than a target 80%  
4 (15) 10 (36) 0.01 
DOT schedule among active TB patients, n=25 (%)3 
     3x/wk DOT 
     5x/wk DOT 













Treatment length, wks  
     Mean ± SD 









Number of rejected videos 
     Mean (SD) 





Unexpected video submission 
     Mean (SD) 





Percent of patients reporting ≥1 side-effect via 
mobile platform (%)4 
 46  
Video length, sec  






Video size, mb  





4 The miDOT video system prompts patients to indicate side-effects prior to video submission 
using checkboxes on the mobile app, with positives resulting in an automatic provider alert.  
The most common symptom reported was ‘abdominal pain’ followed by ‘weakness’. Other 
reported side effects included ‘nausea/vomiting,’ ‘rash,’ ‘sores on lips/mouth,’ ‘joint pain,’ 
‘yellowish skin or eyes,’ and ‘other.’ Of note, some patients digitally captured side-effects 
during the video recordings (e.g. rash). 
 
 30 
Table 3 (1.3): Subset of themes from qualitative analysis.  
Theme Subtheme Representative quote 
Impact of DOT on 
patients 
sDOT can be burdensome for patients “I'm about to start a class, and the class … doesn't really match the time that I 
have to be here to take the pill … I won't be able to do the class, and I need 
the class more than I need [DOT].” 
 sDOT can cause emotional stress “In-person DOT had an emotional impact on me, it was stressful. It made me 
resent [the treatment team].”    
DOT logistics sDOT efficacy is limited by patient factors “[sDOT] just doesn’t work.  Like tonight, I work, I don’t get off until 7:30am and 
then I go to school … there is no time.” 
 vDOT increases access to transient 
patients 
“When I was in Peru for two months the system worked perfectly.  Sometimes 
I even used it outside of the city or at the beach.” 
 vDOT increases access to those with 
complicated work schedules 
“I have very long working hours … it's not possible for me to meet with a DOT 
nurse … with video DOT I could continue with my work and still take the 
medicine.” 
Confidentiality sDOT can violate patient privacy “When somebody has to come to your house driving that [DOH] car, coming in 
… the whole neighborhood's going to look and start asking questions.” 
 vDOT is more private than sDOT “With [vDOT] we can control [the] setting we are in … it's in your hand … just 
avoid taking videos in places where you can be viewed by others … we have 
control.” 
 
Impact of DOT on staff vDOT convenient for staff “Especially for people who have to get up very early in the morning to go to 
work. [vDOT] saves us from having to ... be at their house at 5:00am.” 
 vDOT may threaten livelihood “...the only rumor that I'm hearing, is that some of the DOT workers are 
thinking that [vDOT] is going to take their jobs.” 
Treatment effects of 
vDOT 
vDOT able to shorten therapy “...for patients who aren't [home] during our normal hours, video DOT ... is 
much more effective ... they can dose anytime during the daytime as long as 
they have their phone available ...and they're still getting a counted dose ... we 
can actually count that dose towards their end goal as an observed dose and 
their treatment is shortened by several days.” 
 vDOT allows for observed therapy 7x per 
week 
“The ability to do seven days a week [with vDOT], rather than five, is really 
kind of uncharted territory ... we don't actually know whether people are taking 
their medicines over the weekends, and a lot of programs don't even prescribe 
weekend packs, which when you think about it is sort of odd.” 
vDOT on clinic 
operations 
vDOT may increase clinic capacity “I don't have to spend two hours, three hours in the morning driving all over 
and around the county. It frees me up time-wise enormously. I can see more 
patients in my office.” 
Decisions about DOT 
should be patient 
centered 
Some with poor adherence on sDOT may 
actually do better on vDOT 
“We [had a] patient that was highly non-adherent in standard DOT. She was 
missing three or four doses a week ... we were going to quarantine this 
individual, but [we decided to] attempt video DOT, and ... for about a month or 
two [she] was nearly 100% adherent on a seven-day regimen of medicine on 
video DOT.” 
+ Only subset of themes presented.  For full list see Supplement Tables 3 and 4.  











Table 4 (1.4): Cost analysis of vDOT implementation 
 
* Cost are per-patient and calculated for a standard six-month treatment course. 
1 Base-case assumes a health department vehicle (economy class) used to treat 15 patients per 
year, annualized over the expected lifespan of the vehicle. In the sensitivity analysis we varied 
the number of patients treated annually and calculated alternative pricing structures, including 
ones wherein health care workers utilized a personal vehicle and received mileage 
reimbursement.  
2 Base-case assumes a program-provided smartphone and dedicated clinic computer.  The 
sensitivity analysis incorporates the scenarios wherein a patient phone/data is used for vDOT 
(i.e. no clinic cost incurred).   
3 Miles traveled was estimated from discussions with clinic managers, DOT workers, and 
through the evaluation of monthly gas and mileage reimbursements logs.  Range incorporates 
fluctuations in gas price and variability in the distance between patients.  
4 Software estimates provided directly by emocha Mobile Health Inc., with the base-case 
assuming a flat monthly rate of $50 per patient per month.  The low end estimate assumes free 
software and a patient-provided data plan, while the high end accounts for variable data costs 
and a flat monthly software fee of $100 per patient. Commercial pricing may vary.  
5 Base-case assumes an LPN conducting DOT activities.  Time spent per patient was calculated 
as an average of that observed through time motion studies.  The low range assumes a 
community health worker and the lowest possible estimates of time per patient.  The high 
range assumes an RN (highest salary) and uses the highest possible estimate for time spent 
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Patients can successfully complete TB 
treatment with self-administered therapy ONLY 
(i.e. DOT unnecessary)  
2 (10) 18 (90) 0 (0) 16 (100) 0.16 
DOT provides beneficial social support 19 (95) 1 (5) 
16 
(100) 
0 (0) . 
vDOT is effective for monitoring patient 
adherence 
17 (85) 3 (15) 15 (94) 1 (6) 0.16 
sDOT provides improved adherence over self-
administered  
20 (100) 0 (0) 
16 
(100) 
0 (0) . 
vDOT provides improved adherence over self-
administration 
14 (70) 6 (30) 
16 
(100) 
0 (0) 0.03 
sDOT is burdensome for patients 14 (70) 6 (30) 12 (75) 4 (25) 0.65 
vDOT is burdensome for patients 0 (0) 20 (0) 1 (6) 15 (94) . 
vDOT is more convenient for patients than 
sDOT 
15 (75) 5 (25) 14 (88) 2 (13) 0.56 
sDOT can compromise patient privacy 8 (40) 12 (60) 10 (63) 6 (38) 0.16 
vDOT can compromise patient privacy 2 (10) 18 (90) 2 (13) 14 (88) 0.32 
Comfortable using computers for patient care 19 (95) 1 (5)1 15 (94) 1 (6) 1.00 
Comfortable using smartphones for patient care 19 (95) 1 (5)1 15 (94) 1 (6) . 
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sDOT=standard DOT (in-person), vDOT=video DOT 
+ A five point Likert scale was used.  Agree/strongly agree and neutral/disagree/strongly 
disagree were grouped for the above reporting. 
++ Provider sample size varied pre/post vDOT implementation due to staffing turnover, with 
several staff members coming and going over the course of the study.  Provider cohort 
included all those involved with DOT-related activities, including DOT-workers, nurse case 
managers and TB clinicians.  








































DOT is helpful 15 (60) 10 (40) 6 (67) 3 (33) 0.10 
Self-administration would be preferred 21 (84) 4 (16) 8 (89) 1 (11) 0.56 
sDOT is inconvenient 15 (60) 10 (40) 7 (78) 2 (22) 0.32 
Comfortable using a smartphone 23 (92) 2 (8) 8 (89) 1 (11) . 
Comfortable using a computer 18 (72) 7 (28) 6 (67) 3 (33) 0.32 
Comfortable using video for DOT 23 (92) 2 (8) 7 (78) 2 (22) 0.32 
vDOT is convenient1   8 (89) 1 (11)  
vDOT provides for autonomy1   7 (79) 2 (22)  
miDOT was easy to use   8 (100) 0 (0)  
 
sDOT=standard DOT (in-person), vDOT=video DOT 
+ A five point Likert scale was used.  Agree/strongly agree and neutral/disagree/strongly disagree were 
grouped for the above reporting. 
++ The patient response rate declined post-vDOT due to frequent loss-to-follow-up beyond treatment 
completion.  Notably, vDOT adherence did not differ between those completing and those not completing 
post-intervention qualitative assessment (adherence 89% vs 90%, p=0.92) 




Supplementary Table 3 (1.S.3): Full list of staff themes from qualitative analysis 
STAFF Themes  
Theme Subtheme Illustrative quote 
DOT efficacy DOT is a necessary component of TB 
therapy 
“DOT is absolutely necessary. I think without it, we'd have relapses right and left.” 
Impact of DOT on 
patients  
sDOT can be burdensome for patients  “…some people have to go to school and waiting for the DOT provider … can be a 
problem. Sometimes they miss the bus.” 
 sDOT can cause emotional stress “It's invasive. It's inconvenient. For some people, it's embarrassing or humiliating.” 
 Daily home visits with sDOT help some “There are some people who like having that nurse come to their home … sometimes 
we’re the only person they see throughout the course of the day.” 
 vDOT can be more convenient for 
patients 
“[vDOT] frees the patient out to live a normal life. They don't feel like they are a 
prisoner in their home for nine months or a year.” 
DOT logistics sDOT efficacy is limited by 
environmental factors 
“…when there's power failure, or a weather state of emergency, or a traffic issue … 
we can’t get to the patient … the medicine has to be self-administered … and we 
have to extend the length of patient's treatment.” 
 sDOT efficacy is limited by patient 
factors 
“We’ve had several clients who do seasonal work … they leave at dawn and they 
don't get back home until dusk. My staff routinely works anywhere from 7:30-4:30, and 
so trying to do DOT is impossible.” 
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 vDOT increases access to transient 
patients 
“[vDOT] works very well with immigrant populations ... when they go back [to their 
home country], they can still do videos with us ... for countries in Africa like Liberia 
and Gambia it’s very difficult to find a partner TB clinic ... but now we get to count 
those days because we see them.” 
 With sDOT travel can result in longer 
treatment courses 
“A three day vacation. It's hard because you needs to have packs, and the packs are 
not counted. So the more days off, the more packs you have, the longer is your 
therapy.” 
Confidentiality sDOT can violate patient privacy “I've had people not want to meet at their house … because they don't want their 
neighbors or their families to know that they're being treated for TB.” 
 vDOT is more private than sDOT “You can do [vDOT] in your car on the way to work. You can sit out in your driveway 
and do it.  I think it’s more private than having a nurse come to the house.” 
Impact of DOT on staff sDOT is inconvenient for staff “The DOT worker has to adjust his schedule according to the patient's schedule. 
Sometimes they have to get up very early or drive far distances.”  
 vDOT convenient for staff “Especially for people who have to get up very early in the morning to go to work. 
[vDOT] saves us from having to ... be at their house at 5:00am.” 
 vDOT may threaten livelihood “...the only rumor that I'm hearing, is that some of the DOT workers are thinking that 
[vDOT] is going to take their jobs.” 
Treatment effects of 
vDOT 
vDOT able to shorten therapy “...for patients who aren't [home] during our normal hours, video DOT ... is much more 
effective ... they can dose anytime during the daytime as long as they have their 
phone available ...and they're still getting a counted dose ... we can actually count that 
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dose towards their end goal as an observed dose and their treatment is shortened by 
several days.” 
 vDOT allows for observed therapy 7x per 
week 
“The ability to do seven days a week, rather than five, is really kind of uncharted 
territory ... we don't actually know whether people are taking their medicines over the 
weekends, and a lot of programs don't even prescribe weekend packs, which when 
you think about it is sort of odd.” 
Decisions about DOT 
should be patient 
centered 
vDOT good for those who travel “I’ve had patients that have [traveled] to Vietnam, China, England, Holland, and Los 
Angeles in the past month. So if they have to travel, I think [vDOT] would be a good 
thing.”  
 vDOT may not work in those less tech 
savvy 
“..for the folks ... still using ... older, outdated [phone] models, or that aren't familiar 
with how to use an app ... it may be a little foreboding.” 
 Some may prefer sDOT “Some patients are lonely ... They won't want [vDOT]. They will say, ‘Oh you know, I 
love her to come into my house. Oh, it's nice to see her.’” 
 vDOT should not just be a reward for 
those with good adherence 
“It's almost like [some view] video DOT [as] a prize for those that can show that they 
are going to be compliant.  We nurses don't look at it that way ... If [it]feels like I can 
get better compliance from them by offering them the vDOT option, I would like to 
jump on board quicker.” 
 Some with poor adherence on sDOT 
may actually do better on vDOT 
“We [had a] patient that was highly non-adherent in standard DOT. She was missing 
three or four doses a week ... we were going to quarantine this individual, but [we 
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sDOT=standard DOT (i.e. in-person), vDOT=video DO
decided to] attempt video DOT, and ... for about a month or two [she] was nearly 
100% adherent on a seven-day regimen of medicine on video DOT.” 
vDOT on clinic 
operations 
vDOT may increase clinic capacity “I don't have to spend two hours, three hours in the morning driving all over and 
around the county. It frees me up time-wise enormously. I can see more patients in 
my office.” 
 vDOT costs not as high as feared “Phones may not be as big of a cost as I thought it would be ... Most of our patients 
had a cell phone or an iPad … we've loaned out like two phones.” 
Technology High community level access to 
smartphones  
“We have a fair amount of foreign-born people from all walks of life, and I am always 
amazed at how far advanced everyone is with smartphones ... almost everybody has 
them, almost everybody uses them.” 
 vDOT platform easy to use “I'm so surprised at how user-friendly the software is and how few technical issues 
we've had.” 
Concerns about vDOT Patients taking different medications 
than prescribed 
“When I’m there I’m putting the meds in the packet and I’m putting the contents of the 
packet into your hands but now I’m watching you. I don’t have any control ... so many 
drugs that look similar” 
 Patients gaming the system “There is the possibility that the patient may be deceptive ... They may pretend to take 
it. And you have no assurance that they really took it or dropped it on their lap.” 
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Supplementary Table 4 (1.S.4): Full list of patient themes from qualitative analysis 
PATIENT Themes 
Theme Subtheme Illustrative quote 
DOT efficacy DOT is a necessary component of TB 
therapy 
“…when you start [treatment] … you're sick …  but if you're talking nine months 
medication, by month three [or] four you feel great and you figure, "Oh, I don't need 
[medicine] anymore." But you do. So it's important that [treatment] be monitored.” 
 DOT is unnecessary “… [the nurses] are making sure that I'm taking my medicines on time, but as a 
responsible adult, I can take it myself.” 
 Reminders could replace DOT “I think if they just sent reminders, that would be fine … I would take the medicines.” 
Impact of DOT on 
patients 
DOT can engender perceived stigma “I feel a stigma for having tuberculosis …this [in-person] DOT arrangement, it … 
emphasizes that I have something that not so many people have … we tried first to 
have a person to come during my lunch break and it was just terrible.”  
 sDOT can be burdensome for patients “I'm about to start a class, and the class … doesn't really match the time that I have to 
be here to take the pill … I won't be able to do the class, and I need the class more 
than I need [DOT].” 
 sDOT can cause emotional stress “In-person DOT had an emotional impact on me, it was stressful. It made me resent 
[the treatment team].”    
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 vDOT can allay DOT-related stress “When someone was next to me [for in-person DOT], I felt awkward … they were 
asking me a lot of things, it was stressful. When I got to use the app, it was way 
better. ” 
 sDOT acts as a treatment reminder “[sDOT] is good, because sometimes I forget about my medication, but when 
someone comes to observe you, no problem.” 
 sDOT daily visits are appreciated by 
some 
“I built a relationship with my duty officer. She's a very caring nice person, and I look 
forward to seeing her every day.” 
 vDOT can be more convenient for 
patients 
“I prefer taking the medication during the night time. So [vDOT is] convenient because 
you can take it on your own time.” 
 vDOT preferred over sDOT “I think [vDOT] is 100% better than the standard [DOT] …  definitely better.”  
DOT logistics sDOT efficacy is limited by patient 
factors 
“[sDOT] just doesn’t work.  Like tonight, I work, I don’t get off until 7:30am and then I 
go to school … there is no time.”  
 vDOT increases access to transient 
patients 
“When I was in Peru for two months the system worked perfectly.  Sometimes I even 
used it outside of the city or at the beach.”  
 vDOT increases access to those with 
complicated work schedules  
“I have very long working hours … it's not possible for me to meet with a DOT nurse 
… with video DOT I could continue with my work and still take the medicine.” 
Confidentiality sDOT can violate patient privacy “When somebody has to come to your house driving that [DOH] car, coming in … the 
whole neighborhood's going to look and start asking questions.”  
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sDOT=standard DOT (i.e. in-person), vDOT=video DOT
 vDOT is more private than sDOT “With [vDOT] we can control [the] setting we are in … it's in your hand … just avoid 
taking videos in places where you can be viewed by others … we have control.” 
Treatment effects of 
vDOT 
vDOT provided treatment support “I liked that the application asked me about side-effects.  I sometimes selected 
“nausea,” and then someone would call …we would try different strategies, like trying 
to eat before taking the pills.”   
 vDOT able to shorten therapy “[With vDOT] I was able to take meds in the Dominican Republic.  Before I would 
have had to take [self-administered medication] packets, which are not observed and 
don’t count … my treatment would have been three weeks longer.” 
 vDOT can improve treatment self-
efficacy 
“My ability to continue life in a very normal way [by using vDOT] made it easier to 
carry on with the treatment … the medication was hard … but because I was able to 
travel as I wished it was easier for me to follow the regimen.” 
Technology High community level access to 
smartphones 
“A smartphone is what everybody keeps in their hand all the time … no problem.” 
 Many patients are tech savvy  “Well, I use the internet … Facebook … and things like that … doesn’t everyone?” 
 The miDOT platform was easy to use “You don’t even have to be able to read English.  Once they show you [how to use 




Supplementary Table 5 (1.S.5): Key parameters from cost analysis.    
1 Equipment and consumable costs were estimated through time-motion studies and publicly 
available commercial pricing.  
2 Reflects cost of data plans able to accommodate the minimum needs of the miDOT platform 
(2-3 GB per month).   
3 Estimates of miDOT platform costs were obtained through direct communication with emocha 
Mobile Health Inc.  
4 Hourly wage estimates were obtained through direct communication with TB clinic 








Base-case Low High 
Equipment1 
   
Economy car (DOH vehicle) $16,400 $13,000 $35,000 
Computer $1,000 $600 $1,500 
Smartphone $250 $120 $770 
Consumables1 
   
Mileage reimbursement (per mile) $0.54 - - 
Gasoline (per gallon) $2.20 $1.69 $2.35 
Mobile data plan (per month)2 $32.50 $30.00 $50 
Software (per patient month)3 $50 $0 $100 
Labor (per hour)4 
   
Registered nurse (RN) $38.13 $31.40 $44.85 
Licensed practical nurse (LPN) $30.21 $28.14 $39.06 







































Supplementary Figure 2 (1.S.2): Treatment metrics 
 
1 Inclusive of all observed doses, either by video or in-person.  Includes rejected and 
unexpected videos, the latter representing those submitted on days patient was not planned 
for observation, most often weekend videos submitted by those on M-F vDOT. 
































Supplementary Figure 3 (1.S.3): Site-specific variation in DOT implementation 
structure.   
 
All staff listed below the dashed line were directly involved in DOT implementation.  The 
educational training/background of those conducting DOT ranged from that of a 
community health worker (CHW), with no specific health training (all high school 
graduates), to a licensed practical nurse (LPN) to a registered nurse (RN).  Across sites, 
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India accounts for nearly one quarter of the global tuberculosis (TB) burden. Directly 
observed therapy (DOT), through in-person observation, is recommended in India, 
though implementation has been heterogenous due largely to resource limitations. 
Video DOT (vDOT) is a novel, smartphone-based approach which allows for remote 
treatment monitoring through patient recorded videos. Prior studies in high-income, low 
disease burden settings, such as the United States, have shown vDOT to be a feasible, 
though little is known about the role it may play in resource limited, high burden settings.  
 
Objective. 
To assess the feasibility and acceptability of vDOT for adherence monitoring within a 
resource limited, high TB burden setting of India. 
 
Methods. 
We conducted a prospective, single-arm, pilot implementation of vDOT in Pune, India. 
Outcome measures included adherence (proportion of prescribed doses observed by 
video) and verifiable fraction (proportion of prescribed doses observed by video, or 
verbally confirmed with the patient following an incomplete/unverifiable video 









A total of 25 patients were enrolled. The median number of weeks on vDOT was 13 (11-
16). Median adherence was 74% (IQR 62-84) and median verifiable fraction was 86% 
(IQR 74-98). Greater than 90% of patients reported recording and uploading videos 
without difficulty.  
 
Conclusions. 
We have demonstrated that vDOT may be a feasible and acceptable approach to TB 
treatment monitoring in India. Our work expands the evidence base around vDOT, by 
being one of the first efforts to evaluate vDOT within a resource limited, high TB burden 




















Globally, tuberculosis (TB) is the leading cause of infectious disease-related mortality, 
responsible for 1.6 million deaths annually [1]. Incident TB is higher in India than 
anywhere in the world, with roughly 2.8 million cases, nearly 27% of the global TB 
burden, reported in 2017 [1].  To achieve positive treatment outcomes, adherence to TB 
therapy is critical [2, 3]. However, socioeconomic and health systems barriers in India 
are common, and negatively impact adherence [4-6]. Failure to complete treatment can 
lead to relapse and the emergence of multidrug-resistant TB (MDR-TB), resulting in 
further disease transmission. 
 
The World Health Organization (WHO) encourages the tailored use of multidimensional 
adherence interventions, including social, material and psychological support. It 
additionally emphasizes monitoring through directly observed treatment (DOT) [7]. 
Compared to self-administered therapy, those managed with DOT have demonstrated 
an improved rate of treatment completion [7, 8]. Completion of therapy is vital not only 
for the patient, but also the community, as public health efforts to mitigate disease 
spread require treatment success.  
 
Unfortunately, DOT is often burdensome for patients and, paradoxically, can have a 
negative impact on adherence for some [9]. In India, DOT has, historically, been largely 
clinic-based (though there are differences in the public and private sector), wherein 
patients are required to bear the financial and logistical burden of frequent travel to and 
from the clinic for treatment monitoring. In doing so, patients risk lost wages due to time 




process that can be onerous and prohibitive in resource constrained settings. While 
DOT is formally recommended under the current TB treatment guidelines set forth by 
India’s Revised National Tuberculosis Control Program (RNTCP), in practice, DOT 
implementation (i.e. observing and documenting each prescribed dose) in the 
community is inconsistent and associated barriers can lead to treatment default [10-16]. 
 
More recently, video directly observed therapy (vDOT) has been introduced as a 
patient-centered alternative to in-person DOT. Herein, pill ingestion is monitored 
remotely via digital video capture. vDOT has been implemented using synchronous 
technologies [17-20], such as Skype and FaceTime, as well as asynchronous ones [21, 
22], wherein recorded videos are uploaded and digitally stored for future review. This 
latter method allows for video capture to occur at times convenient for the patient and 
eliminates the need for vDOT to be scheduled around staff availability. Recent work has 
shown asynchronous vDOT to be feasible, well received (by patients and providers), 
and associated with high rates of treatment adherence [21-28]. Further, two economic 
evaluations in the United States have suggested vDOT to be cost-savings over in-
person DOT [21, 28]. These encouraging findings have led both the Centers for Disease 
Control (CDC) and the WHO to suggest vDOT as a viable alternative to in-person DOT 
[29-31]. 
 
While data on vDOT is becoming increasingly robust, vDOT has yet to be rigorously 
evaluated within low/middle income countries of high disease burden, such as India. 
Despite resource constraints, cellular technology has spread rapidly through India. As of 




smartphone users within the country, suggesting that vDOT may have a role in this 
setting [32, 33].  What’s more, recent changes to the RNTCP guidelines have prioritized 
daily therapy (i.e. 7 days/week) over thrice-weekly therapy (i.e. 3 times/week), with DOT 
expected daily, a change which only further questions the feasibility of in-person DOT 
within a system already stretched thin, and underscores the need for alternative 
approaches to adherence monitoring and support [14, 34, 35]. 
 
To address this critical knowledge gap, we conducted a prospective pilot of vDOT in 
Pune, India. Specifically, we address the feasibility and acceptability of vDOT within this 




We conducted a prospective, single-arm, pilot implementation of vDOT in Pune, India 
with the aim to assess its feasibility and acceptability within a resource-limited, high 
disease burden setting. The mobile app emocha video DOT (emocha Mobile Health 
Inc.; product formerly known as miDOT) was used for treatment monitoring and 
adherence support (Figure 1). emocha is HIPAA-compliant (i.e. meets internet security 
and privacy standards keeping with US HIPAA regulations) and allows for 
asynchronous vDOT (Figure 2). The study was conducted at the Dr. D.Y. Patil Medical 
College Center and took place between January 2017 and June 2018. Study 
procedures were approved by the local institutional ethics committee and the 







Dr. D.Y. Patil Medical College Hospital is a private hospital, which contains a 
government (public) TB treatment center (DOTS center) as a Public-Private Mix (PPM) 
initiative. Patients diagnosed and/or treated with TB at either Dr. D.Y. Patil or at local 
DOTS centers were eligible for the study. Inclusion required age >18, signed informed 
consent and >2 remaining months of TB therapy. Patients with multi-drug resistant 
(MDR) disease and HIV were excluded. Given this was a pilot study, we enrolled a 
convenience sample. Some patients were approached at the time of diagnosis, though 
many were assessed for eligibility mid-treatment. Those not participating in the study 
received treatment and observation as per the local standard of care. Local guidelines 
recommend DOT for all intensive phase doses and for at least one dose per week 
during the continuation phase [14], though implementation is heterogenous and largely 
determined by local resources and patient preference [16] [personal communication Dr. 
Tushar Sahasrabudhe, November 2018]. 
 
Prior to enrollment, patients were required to establish basic smartphone proficiency 
and demonstrate the ability to successfully navigate the emocha app. A version of 
emocha translated into Marathi (the primary local language) was available to those with 
limited English. Patients without access to a smartphone were provided one by the 
study. Regardless of the device used, each participant was provided Rs. 200 (~US $3) 
each month to cover the cost of video submissions, as well as a one-time incentive 







Overall 35 patients based on convenient sampling method were selected for this study. 
All patients provided written informed consent and were allowed to withdraw from the 
study at any time. Demographic information and specifics related to each participants' 
medical history and TB diagnosis were collected using a standardized CRFs (case 
report forms). Data was subsequently entered into a digital database by study staff. 
During their first study visit, each participant was introduced to vDOT by a study staff 
member, who provided each with a unique username/password and conducted a step-
by-step tutorial outlining the process for how to create and submit a treatment video. 
Patients were then observed as they attempted to submit a “dummy” video 
independently. Added training was provided on an as-needed basis.   
 
Prior to formal enrollment, patients underwent a conditional one-week run-in period, 
during which they were closely monitored for their continued ability to successfully 
record and submit videos. Any technical or logistical barriers arising during this period 
were addressed prior to formal study enrollment, which was only able to occur following 
successful completion of this trial period. For those enrolled, vDOT continued through 
treatment completion, or until consent was withdrawn. Text message reminders, via the 
emocha app, were automatically sent to patients in the absence of expected video 
submissions. All incomplete or unverifiable videos (e.g. medication could not be seen or 
video did not transmit due to network issue) were followed-up with a staff phone call to 







Feasibility was assessed by two primary outcomes. The first was treatment adherence, 
or the proportion of all prescribed treatment doses directly observed (by video). As 
noted above, incomplete or unverifiable videos, were followed-up with a phone call for 
verbal verification. As such, a second metric, verifiable fraction, was used to describe 
the proportion of all prescribed doses that were either directly observed (by video) or 
verbally confirmed (following incomplete/unverifiable videos). All data analysis was 
completed in STATA 14.  
 
Acceptability  
To assess vDOT acceptability among patients a post-treatment survey was 
administered; a series of categorical and Likert-scale questions addressed issues such 
as mobile phone and internet access, emocha ease of use, convenience and privacy. 
To increase our understanding of potential implementation barriers, patients were also 
informally asked to comment on their experiences and to highlight any challenges or 
concerns they had related to the use of vDOT. Patient responses were noted by study 
staff at the time of survey administration. Staff were also asked to comment on patient-
level barriers observed during the study. 
 
RESULTS 
Of 35 patients who were consented and initiated the run-in phase (Figure 3), 10 did not 
complete the run-in and left the study. Reasons for run-in failure were related to both 




connectivity) as well as psychosocial ones (e.g. concerns regarding privacy). Twenty-
five patients were ultimately enrolled, and formally initiated on vDOT with emocha. 
There was no study drop out and all 25 patients completed therapy on vDOT.  
 
Patient characteristics are described in Table 1. The median age was 27 years (IQR 24-
42), 40% (10 of 25) were female and 72% (18 of 25) reported their local language as 
“Marathi.” Most patients were low income with a monthly income less than INR 16000 
(US ~$225). The majority of patients (88%, 22 of 25) had access to a smart phones and 
internet. Three patients (12%, 3 of 25) required the use of a study phone. Seventy-two 
percent patients (18 of 25) had pulmonary TB, while the remainder (28%) had extra 
pulmonary disease.  
 
The majority of patients were initiated on vDOT during the continuation phase (80%, 20 
of 25), with 20% (5 of 25) beginning during the intensive phase. The median number of 
weeks on vDOT was 13 (IQR 11-16), with a range of 9 to 23 weeks (Table 2). Eighty 
percent of patients (20 of 25) received daily (7x per week) therapy, while 20% (5 of 25) 
received an intermittent, thrice weekly (3x per week) regimen. No in-person DOT was 
documented either before or after implementation of vDOT. Overall, 60% (15 of 25) of 
patients reported at least one treatment-related side effect. The most commonly 
reported symptoms were the following: nausea/vomiting (8 of 15), abdominal pain (3 of 






Median adherence on vDOT was 74% (IQR 62-84) (Table 2). After including verbally 
verified doses (following unverifiable or incomplete videos), the median verifiable 
fraction was 86% (IQR 74-98). An average of 91 videos (SD ±53) were submitted per 
patient. The average number of rejected videos per patient was 1.6 (SD ± 2.4), with 
56% (14 of 25) having no rejected videos at all. The most common reasons for video 
rejection were "poor quality of video" and "medication not fully seen." The median video 
length was 44 seconds (IQR 31-52), and associated with a median file size of 1.5 mb 
(IQR 1.1-1.7).  
 
Acceptability 
A total of 22 post-treatment surveys were completed. Three patients declined 
participation. Study outcomes for those declining involvement were similar to those of 
the general study population; each patient completed >14 weeks on vDOT with an 
adherence > 70%.  
 
Ninety one percent of surveyed patients described emocha as “easy to use” (Table 3). 
All patients (100%, 22 of 22) reported being able to record videos without difficulty and 
95% (21 of 22) were able to upload without difficulty. Ninety one percent found text-
message reminders helpful. Further, all found they were able to communicate concerns 
and medication side-effects effectively through the emocha platform.   The majority felt 
vDOT would be more convenient (91%, 20 of 22) and preferred (91%, 20 of 22) over in-
person DOT (Table 4). While 82% (18 of 22) felt vDOT would preserve patient privacy 






Study coordinator notes were reviewed and summarized (Figure 4). Broadly, these 
notes revealed patient-level barriers impacting the successful implementation and 
utilization of vDOT (Figure 4). Included were psychosocial factors, such as the privacy 
concerns and stigma, as well as mental health barriers. Despite survey data suggesting 
that most were able to record and upload videos without issue, poor connectivity and 
cellphone-related challenges (e.g. SIM card malfunction) were noted in a few cases.  
 
DISCUSSION 
Our pilot study suggests that vDOT may be a feasible option for verification of 
medication adherence for TB patients in India. Among enrolled participants that 
completed a short run-in period to assess technological literacy, we found that a median 
74% of all prescribed doses were observed. Further, when including doses verbally 
confirmed (following incomplete video submissions) the proportion of verified doses, or 
verifiable fraction, increased to 86% (based on 1,722 submitted and reviewed videos), 
exceeding the adherence goal of >80% set forth by current treatment guidelines [29]. 
What’s more, this degree of adherence is comparable to that described using vDOT in 
other settings, such as the USA, and advances current evidence supporting vDOT, as 
prior work has largely focused on implementation within resource rich settings [17, 21, 
28, 36]. To the best of our knowledge, this is the first reported use of vDOT in India.  
 
Our demonstration of vDOT feasibility within the Indian context is both timely and critical 
given the recent RNTCP guideline changes emphasizing the need for daily over 




principle of direct treatment observation, has been in place in India for over two 
decades, in practice, DOT implementation has been inconsistent.  
 
In Pune, our experience has been that patients are often provided medication weekly or 
biweekly, with adherence monitoring largely based on self-report. At best, clinic 
services, including in-person DOT, are generally available six days per week, permitting 
a maximum of only 85% of prescribed (daily) doses to be observed. In contrast, by 
decoupling video capture from provider review, asynchronous vDOT potentially allows 
for all (100%) doses to be observed and obviates the need to coordinate DOT around 
staff availability. 
 
To successfully, and sustainably, implement DOT in India, alternatives to in-person 
DOT are clearly needed. Video DOT has the potential to be this alternative and to fill the 
needed gap. Our study is among the first in a resource limited setting to demonstrate 
that daily therapy can be confirmed through the use of innovative mobile technologies. 
Video DOT saves health care worker time and obviates the need for in-person visits to 
observe treatment [23]. For settings where home-visits are employed solely for DOT, 
vDOT may reduce costs and save time even further[19, 21, 28, 37, 38]. Video DOT may 
also have other previously unrecognized benefits related to infection control. Provisions 
for personal protective equipment (i.e., masks for health care workers) or environmental 
controls (isolation rooms) are limited in India; vDOT offers a mechanism to closely 
monitor patients while reducing potential transmission opportunities. Additionally, we 
observed that patients derived benefit from avoiding frequent clinic visits, for which 




solid evidence of treatment adherence. Nevertheless, our study also highlights a need 
for patient training (e.g., run-in period with onboarding to the technology), counseling, 
and follow-up in cases of missed doses to assure successful treatment completion.  
 
Of note, India has already endorsed another electronic form of treatment monitoring, 
99DOTs, which requires patient to place an incomplete phone-call to a provided number 
at the time of pill ingestion [12, 34]. While 99DOTS may be a feasible means for basic 
adherence monitoring [39], vDOT has the distinct advantage of providing video 
confirmation of pill ingestion. It is also important to consider that the usage of vDOT 
allows for adherence support in addition to adherence tracking. The platform used in 
this study captures side effects and TB symptoms, and videos can also be used to 
notify providers of treatment concerns, such as rashes, which can be preliminarily 
evaluated from afar through submitted videos. Moreover, the current platform allows 
automated messaging reminders, which patients reported to be a benefit. Newer 
versions of the software offer secure chat functionality (with health care providers) and 
case management tools, which may further support treatment adherence. India recently 
rolled out a Direct Benefits Transfer (DBT) scheme, which encourages treatment 
adherence through the use of financial incentives (Rs. 500 per month while on therapy) 
[40, 41]. 99DOTS is currently being used as a mechanism to monitor treatment 
adherence, but is limited. For the reasons noted above, a more reliable, tamper-proof, 
means of adherence monitoring would be beneficial.  
 
While our work supports further evaluation of vDOT within India, we acknowledge 




vDOT to be feasible in one location, it's acceptability and feasibility in other parts of 
India remains unknown. Secondly, we were unable to compare adherence on vDOT to 
that under the existing standard of care, which at our site was primarily self-
administration (thus precluding documentation of pre-study adherence). On the other 
hand, our findings suggest that vDOT implementation could substantially improve 
adherence documentation, as compared to current practice. Through broader 
implementation, vDOT has the potential to enable enhanced accountability among TB 
clinics with regards to treatment adherence. Improvements in documentation would also 
increase the availability of high-quality data on TB treatment completion for public health 
reporting practices. Finally, whether vDOT is associated with improved patient 
outcomes compared to standard of care is still unknown and was not assessed within 
the scope of this pilot study. 
 
We also acknowledge a significant attrition over the course of our run-in period. One 
third of those who consented did not ultimately participate in the study. Drop out during 
this period was largely driven by technologic barriers related either to infrastructure (e.g. 
inconsistent cellular coverage) or inability/unease with smartphone operation. Further, 
despite the fact that we utilized a HIPAA compliant app (emocha) with stringent security 
controls, several participants withdrew consent over privacy concerns. Some patients 
noted a fear that their treatment videos might end up publicly viewable on the internet.  
While cellphone technology has spread rapidly across India, cellular coverage remains 
incomplete and not all have become immediately facile with the technology. With time, 
these barriers may diminish. On the other hand, usage of a run-in was advantageous in 




candidates for vDOT. In our study, all those completing the run-in, and enrolling in the 
study, successfully finished therapy on vDOT.  
 
Despite its promise, there remain questions regarding vDOT that must be addressed. 
Larger controlled and comparative trials will be needed to better evaluate the 
effectiveness of vDOT against the current standard of care or alternative technologies in 
resource limited, high disease burden settings. Future studies addressing cost and cost-
effectiveness are also needed. Lastly, in other settings, such as the US, vDOT has 
successfully been coupled with individualized case management to allow real-time 
intervention after missed doses; the role of this approach in India is unknown [21].  
 
Overall, our work has shown that despite socioeconomic and structural barriers, vDOT 
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Table 1 (2.1): Patient and disease characteristics 
 
Variable All patients (n=25) 
Age, year (median, IQR) 27 (24-42) 
Female, n (%) 10 (40) 
Indian state of origin, n (%)  
 Maharashtra 18 (72) 
 Haryana 2 (8) 
 Karnataka 1 (4) 
 Tamil Nadu 1 (4) 
 Other 3 (12) 
Primary language, n (%)  
 Marathi 18 (72) 
 Hindi 6 (24) 
 Kannada 1 (4) 
Employed, n (%) 10 (40) 
Average monthly income (Rs), n (%)  
 >16,000 0 (0) 
 8,000 – 16,000 13 (52) 
 4,000 - 8,000 6 (24) 
 2,000 – 4,000 0 (0) 
 <2,000 6 (24) 
Homeless, n (%) 1 (4) 
Residence, n (%)  
 Urban 21 (84) 
 Rural 4 (16) 
Married, n (%) 13 (52) 
Primary mode of transportation, n (%)  
 Private vehicle 0 (0) 
 Bus/train 0 (0) 
 Auto-rickshaw 8 (32) 
 Other private transportation 17 (68) 
Substance use, n (%) a  
 Alcohol 1 (4) 
 Tobacco use 0 (0) 
 Illicit drug use 0 (0) 
Medical comorbidities, n (%) a  
 Diabetes 3 (12) 
 Hypertension 1 (4) 
 Cancer 0 (0) 
Technology, n (%)  
 Regular access to a smartphone 22 (88) 
 Daily access to Wi-Fi or cellular data 22 (88) 
 Used personal device for study 22 (88) 
TB category, n (%)  
 Pulmonary b  
  Smear positive 14 (56) 
  Smear negative 4 (16) 
 Exclusively extra pulmonary 7 (28) 
 
a Categories not mutually exclusive, each out of 25 total participants.   




Table 2 (2.2): Video DOT outcomes and data utilization  
 
Variable vDOT (n=25) 
Adherence (%) a  
 Median (IQR) 74 (62-84) 
Verifiable fraction (%) b  
 Median (IQR 86 (74-98) 
Dosing frequency, n (%)  
 3x/wk DOT 5 (20) 
 7x/wk DOT  20 (80) 
Treatment phase at enrollment, n (%)  
 Intensive phase 5 (20) 
 Continuation phase 20 (80) 
Number of weeks on vDOT, median (IQR) 13 (11-16) 
Total uploaded videos (n) c 1,722 
Mean uploads per patient, mean (SD) 91 (53) 
Number of rejected videos per patient  
 Mean (SD) 1-6 (2.4) 
 Range 0-8 
Video length, sec  
 Median (IQR) 44 (31-52) 
Video size, mb  
 Median (IQR) 1.5 (1.1-1.7) 
 
a Proportion of total prescribed doses completed under video observation. 
Of note, no in-person DOT was noted either before or after the 
implementation of vDOT. 
b Proportion of total prescribed doses verified by any means. Verification 
included successful observation by video upload, as well verbal dose-
confirmation (by phone or in-person) following the submission of an 
incomplete, or poor quality, video.  
c Total video uploads across all patients over the length of the study. 












Table 3 (2.3): Responses from patient agreeability survey 
 




emocha was easy to use 20 (91) 2 (9) 
I was able to record videos without difficulty 22 (100) 0 (0) 
I was able to upload videos without difficulty 21 (95) 1 (5) 
emocha text-message reminders were helpful 20 (91) 2 (9) 
I was able to communicate concerns and side effects using emocha effectively 22 (100) 0 (0) 
 
A five-point Likert scale was used.  Agree/strongly agree and neutral/disagree/strongly disagree 
were grouped for the above reporting. Three patients declined participation. Study outcomes for 
those declining involvement were similar of the general study population; each patient completed 































































a In-person DOT, either prior to enrollment or while on vDOT, was 
inconsistently performed and/or documented based on chart 
reviews. Answers referring to in-person DOT are therefore 














Survey questions: categorical All patients 
n (%) 
Videos were most often uploaded using  
 WiFi at the clinic 0 (0) 
 WiFi at home or other location 0 (0) 
 Cellular data (3G/4G) 22 (100) 
Which better preserves patient privacy? a  
 vDOT 18 (82) 
 In-person DOT 4 (18) 
 No preference 0 (0) 
Which is more convenient? a  
 vDOT 20 (91) 
 In-person DOT 2 (9) 
 No preference 0 (0) 
Preference for therapeutic monitoring a  
 vDOT 20 (91) 
 In-person DOT 2 (9) 










The patient-facing portion of the platform (i.e. the mobile app) allows patients to record, 
and transmit, treatment videos. The interface also prompts patients to report any 
medication-related side effects (by checking off relevant symptoms from a pre-
populated list). Through a calendar function, patients are able to review treatment 
progress and track adherence. Use of the software requires a camera-enabled device 
(tablet or smartphone), with at least intermittent access to WiFi or cellular data. The app 
supports both Android and iOS operating systems.  The provider portion of the platform 
can be accessed on a desktop, laptop, tablet or smartphone with internet access using 




is used by medical staff to review treatment videos. Given the system’s asynchronous 
nature, submitted videos could can be reviewed at any time following digital capture and 
transmission. Through this interface providers are also notified of any patient-reported 









































Figure 2 (2.2): Security and data flow on vDOT (emocha) 
 
 
Video-capture occurs via the emocha app. Patient data is encrypted locally (within the 
smartphone) and uploaded (when internet available) immediately to a secure cloud 
storage site via an encrypted transmission tunnel. In the event that the device loses 
internet service, or does not have access to internet service during video capture or 
upload, the videos (or any untransmitted component) remain encrypted on the device; 
all videos are uploaded automatically to secure servers when connection is restored 
(wifi or cellular data).  Following transmission, videos are automatically wiped from 
smartphone memory. Encrypted patient data, therefore, remains within the device only 
for the period between video-capture and web upload. Providers are able to access 
uploaded data via a secure web interface, through which they review submitted videos 


















Figure 4 (2.4): Patient-level barriers to successful vDOT utilization.  
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